Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
J&J subsidiary files for bankruptcy for third time to settle talc lawsuits
05:13pm, Monday, 23'rd Sep 2024
Under the proposal, Johnson & Johnson will pay $8B to claimants over 25 years.
Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time
04:00pm, Monday, 23'rd Sep 2024
The higher settlement offer and a high percentage of claimant support may improve JNJ's chances of success after the previous two failures.
Johnson & Johnson: A Sell-Rated Dividend King
12:12pm, Monday, 23'rd Sep 2024
Johnson & Johnson (JNJ) is showing signs of a topping pattern with negative divergences in momentum indicators, suggesting potential price weakness ahead. The stock is expensive based on forward P/E a
J&J talc subsidiary files third bankruptcy case in attempt to resolve cancer lawsuits
07:48am, Monday, 23'rd Sep 2024
CNBC's Becky Quick reports on the latest news.
Is Johnson & Johnson Stock a Buy?
11:15am, Saturday, 21'st Sep 2024
Johnson & Johnson is capturing strong demand across its pharmaceutical and medtech portfolio. New product launches and an extensive pipeline of candidate drugs support a positive growth outlook.
Attorneys Vow to Oppose J&J's Third Bankruptcy Attempt
06:53pm, Friday, 20'th Sep 2024
HOUSTON--(BUSINESS WIRE)--Attorneys representing tens of thousands of women with ovarian cancer linked to use of Johnson & Johnson (NYSE:JNJ) talc products say they will immediately seek dismissal of
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”) announced that its subsidiary, Red River Talc LLC (“Red River”), filed a voluntary prepackaged Chapter 11 ba
J&J subsidiary files for bankruptcy to advance $8 billion talc settlement
03:39pm, Friday, 20'th Sep 2024
A Johnson & Johnson subsidiary filed for bankruptcy for a third time on Friday as the healthcare giant seeks to advance an approximately $8 billion proposed settlement that would end tens of thousands
J&J's Rybrevant Receives FDA Nod for Expanded Use in NSCLC
02:36pm, Friday, 20'th Sep 2024
With this approval, JNJ's Rybrevant is now approved for a total of four indications in the United States.
Approval based on compelling safety and efficacy from the Phase 3 MARIPOSA-2 study, marking the third new indication for RYBREVANT® this year, with four indications overall RARITAN, N.J. , Sept. 17,
Johnson & Johnson Commemorates 50 Years in Singapore with a Series of Events Marking a Remarkable Milestone
08:00pm, Wednesday, 18'th Sep 2024
SINGAPORE, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Johnson & Johnson (J&J), a leading healthcare company, announced its 50th anniversary in Singapore. Guided by Our Credo to put the needs and well-being of
Passive Income Investors Are Grabbing These 5 Dividend Kings Before the Rate Cuts
10:49am, Tuesday, 17'th Sep 2024
24/7 Wall St. Insights The futures market has 100% priced in a 25-basis-point rate cut.
Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
07:38am, Tuesday, 17'th Sep 2024
Dividend stocks are all-weather investments for buy-and-hold investing because they can help reduce portfolio volatility while generating income. Buying them when they are down and building a solid po
Pick Disney Over Johnson & Johnson Stock
07:00am, Tuesday, 17'th Sep 2024
Given its attractive valuation, we believe that Disney stock (NYSE: DIS) is currently a better pick than the pharmaceuticals bellwether – Johnson & Johnson stock (NYSE: JNJ). The decision to invest
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
06:51pm, Monday, 16'th Sep 2024
Johnson & Johnson (JNJ) closed the most recent trading day at $166.99, moving +0.89% from the previous trading session.
